| scholarly article | Q13442814 |
| P356 | DOI | 10.1152/AJPENDO.00038.2012 |
| P698 | PubMed publication ID | 22374753 |
| P50 | author | monica montagnani | Q57436148 |
| Maria A. Potenza | Q46406484 | ||
| P2093 | author name string | Francesco Addabbo | |
| Luca Sgarra | |||
| P2860 | cites work | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
| Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells | Q22253424 | ||
| PPAR attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells | Q57892049 | ||
| Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators | Q28281001 | ||
| Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension | Q28301973 | ||
| Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) | Q28306815 | ||
| Proteomic-based detection of a protein cluster dysregulated during cardiovascular development identifies biomarkers of congenital heart defects | Q28509745 | ||
| Peroxisome proliferator-activated receptor gamma inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells | Q28580270 | ||
| Molecular regulation of vascular smooth muscle cell differentiation in development and disease | Q29615194 | ||
| TRP channels | Q29616673 | ||
| The pathobiology of diabetic complications: a unifying mechanism | Q29617766 | ||
| The Bcl-2 protein family: arbiters of cell survival | Q29618158 | ||
| Cellular mechanisms of insulin resistance | Q29619549 | ||
| A central role for JNK in obesity and insulin resistance | Q29619778 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial | Q30438736 | ||
| Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial | Q31029646 | ||
| The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells | Q31921949 | ||
| Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway | Q32059552 | ||
| Exercise training decreases store-operated Ca2+entry associated with metabolic syndrome and coronary atherosclerosis | Q33573616 | ||
| Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study | Q33575808 | ||
| Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products | Q33595290 | ||
| High glucose-induced oxidative stress increases transient receptor potential channel expression in human monocytes | Q33750707 | ||
| Impaired peroxisome proliferator-activated receptor-gamma contributes to phenotypic modulation of vascular smooth muscle cells during hypertension | Q33810041 | ||
| Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration | Q33819486 | ||
| A randomized trial of therapies for type 2 diabetes and coronary artery disease | Q33827504 | ||
| Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 | Q33880303 | ||
| Endothelial dysfunction in diabetes. | Q33959485 | ||
| Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone | Q34123137 | ||
| Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality | Q34127761 | ||
| Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes | Q34150577 | ||
| Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release | Q34185006 | ||
| Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose | Q34204855 | ||
| Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial | Q34242531 | ||
| Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent | Q34256957 | ||
| Thiazolidinediones | Q34346862 | ||
| 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro | Q34452063 | ||
| Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells | Q34509942 | ||
| Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis | Q37731651 | ||
| Management of diabetes mellitus in patients with cardiovascular disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial | Q37763363 | ||
| Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update. | Q37843184 | ||
| Cardiovascular complications in diabetes: lessons from animal models. | Q37861826 | ||
| Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus | Q37908528 | ||
| Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma | Q38354039 | ||
| Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with c | Q38375360 | ||
| Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels | Q39575691 | ||
| Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. | Q39648063 | ||
| Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress: a serial, in vivo intravascular ultrasound study | Q39876880 | ||
| Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis | Q40397866 | ||
| Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. | Q40470341 | ||
| Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. | Q40480010 | ||
| MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive ox | Q40726966 | ||
| Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). | Q40799734 | ||
| Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation | Q40884375 | ||
| PPARgamma agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression | Q40924711 | ||
| Peroxisome proliferators activate extracellular signal-regulated kinases in immortalized mouse liver cells | Q41109889 | ||
| Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis | Q41491513 | ||
| Expression and function of PPARgamma in rat and human vascular smooth muscle cells | Q41725857 | ||
| Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells | Q41734805 | ||
| Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway | Q42477113 | ||
| Insulin inhibits migration of vascular smooth muscle cells with inducible nitric oxide synthase | Q42482576 | ||
| Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes | Q42487904 | ||
| Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance | Q34577169 | ||
| Optimal medical therapy with or without PCI for stable coronary disease | Q34612445 | ||
| Improved insulin sensitivity by calorie restriction is associated with reduction of ERK and p70S6K activities in the liver of obese Zucker rats | Q34630250 | ||
| Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis | Q34634794 | ||
| Diabetes and atherosclerosis: epidemiology, pathophysiology, and management | Q34646074 | ||
| The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes | Q34655580 | ||
| Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death | Q34659938 | ||
| Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis | Q34686103 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial | Q34985342 | ||
| Pleiotropic effects of glitazones: a double edge sword? | Q35025858 | ||
| AKT phosphorylation is essential for insulin-induced relaxation of rat vascular smooth muscle cells | Q35131182 | ||
| Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes | Q35140825 | ||
| Metabolic and molecular basis of insulin resistance | Q35148800 | ||
| Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms | Q35596926 | ||
| Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus | Q35609174 | ||
| Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease | Q35633275 | ||
| Vascular smooth muscle cell migration: current research and clinical implications | Q35647930 | ||
| Pathogenesis of type 2 diabetes mellitus | Q35861736 | ||
| Molecular mechanisms of insulin resistance that impact cardiovascular biology | Q35927757 | ||
| Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension | Q36015782 | ||
| Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. | Q36450952 | ||
| The insulin resistance syndrome: physiological considerations | Q36806509 | ||
| Cardiovascular actions of insulin | Q36831533 | ||
| Diabetes mellitus as a prothrombotic condition | Q36889156 | ||
| Diabetes mellitus and macrovascular disease: mechanisms and mediators | Q36934274 | ||
| Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. | Q37103503 | ||
| Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies | Q37172727 | ||
| Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle | Q37175187 | ||
| Increased rhythmicity in hypertensive arterial smooth muscle is linked to transient receptor potential canonical channels. | Q37295391 | ||
| Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance. | Q37303369 | ||
| Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature | Q37337305 | ||
| A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn | Q37429296 | ||
| Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. | Q37485515 | ||
| Vascular actions of insulin with implications for endothelial dysfunction | Q37505788 | ||
| Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. | Q42536498 | ||
| Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content | Q42578006 | ||
| Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus | Q42604247 | ||
| The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk | Q42831071 | ||
| PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation | Q42832963 | ||
| Revisiting the rosiglitazone story--lessons learned | Q42957422 | ||
| Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial | Q42995214 | ||
| Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation | Q43088578 | ||
| A sphingosine-1-phosphate-activated calcium channel controlling vascular smooth muscle cell motility | Q43138558 | ||
| The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway | Q43211170 | ||
| Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients | Q43292964 | ||
| Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia | Q43684759 | ||
| Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells | Q43798535 | ||
| Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration | Q43798813 | ||
| PPAR activators inhibit endothelial cell migration by targeting Akt. | Q44020948 | ||
| Insulin inhibits PDGF-directed VSMC migration via NO/ cGMP increase of MKP-1 and its inactivation of MAPKs | Q44101856 | ||
| Antiinflammatory and antiarteriosclerotic effects of pioglitazone | Q44201670 | ||
| Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells | Q44275923 | ||
| Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model | Q44287903 | ||
| Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study | Q44403585 | ||
| Fas and Fas-associated death domain protein regulate monocyte chemoattractant protein-1 expression by human smooth muscle cells through caspase- and calpain-dependent release of interleukin-1alpha. | Q44567717 | ||
| Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator–Activated Receptor-γ Agonist in Hypercholesterolemia | Q44650457 | ||
| In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control | Q44745053 | ||
| Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients | Q45285409 | ||
| Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma | Q45285602 | ||
| New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9. | Q46129148 | ||
| Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo | Q46137342 | ||
| Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. | Q46406338 | ||
| Rosiglitazone promotes atherosclerotic plaque stability in fat-fed ApoE-knockout mice | Q46500891 | ||
| Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers | Q46588893 | ||
| Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects | Q46601696 | ||
| Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms | Q46601702 | ||
| Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. | Q46731659 | ||
| Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules. | Q46841200 | ||
| Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. | Q46960665 | ||
| Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. | Q46966126 | ||
| Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease | Q46989695 | ||
| Coculture with endothelial cells enhances vascular smooth muscle cell adhesion and spreading via activation of beta1-integrin and phosphatidylinositol 3-kinase/Akt. | Q51098540 | ||
| Pioglitazone for diabetes prevention in impaired glucose tolerance. | Q51161029 | ||
| Carotid arterial stiffness is marginally higher in the metabolic syndrome and markedly higher in type 2 diabetes mellitus in patients with manifestations of arterial disease. | Q51475362 | ||
| Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance. | Q51484642 | ||
| Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats. | Q51564567 | ||
| Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. | Q51972429 | ||
| Regulation of vascular smooth muscle cell proliferation: role of NF-kappaB revisited. | Q52939122 | ||
| Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. | Q53606830 | ||
| High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. | Q54064851 | ||
| Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. | Q54136935 | ||
| Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. | Q54346849 | ||
| P433 | issue | 10 | |
| P921 | main subject | (RS)-rosiglitazone | Q424771 |
| pathophysiology | Q1135939 | ||
| P304 | page(s) | E1171-82 | |
| P577 | publication date | 2012-02-28 | |
| P1433 | published in | American Journal of Physiology - Endocrinology and Metabolism | Q15765671 |
| P1476 | title | Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology | |
| P478 | volume | 302 |
| Q50154239 | Beneficial effects of rosiglitazone and losartan combination in diabetic rats |
| Q35121959 | Milk-derived tripeptides IPP (Ile-Pro-Pro) and VPP (Val-Pro-Pro) promote adipocyte differentiation and inhibit inflammation in 3T3-F442A cells |
| Q27000731 | Role of lipotoxicity in endothelial dysfunction |
| Q36672866 | The endothelium in diabetes: its role in insulin access and diabetic complications |
Search more.